Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway

Oncogene volume 22, pages 3463–3471 (2003)Cite this article

Abstract

We isolated the MAL (T-lymphocyte maturation associated protein) gene from differentially expressed products of esophageal epithelium relative to esophageal carcinoma tissues. The Mal protein has been demonstrated as being a component of the protein machinery for apical transport in epithelial polarized cells. In this study, we describe the reduced expression of MAL in all 39 cases of esophageal carcinoma tested and 60 other human carcinomas. MAL gene transcription was induced in three out of 13 esophageal carcinoma cell lines by treatment with the demethylating agent 5-aza-2′-deoxycytidine (DAC), and in nine additional cell lines by simultaneous treatment with trichostatin A, an inhibitor of deacetylation, and DAC. We established a stable MAL gene transfectant whose expression was regulated by subcutaneous doxycycline injection in nude mice. Tumor growth was suppressed in cells expressing TE3-MAL compared with TE3 parent cells or cells not expressing TE3-MAL with doxycycline injection (20 μg/body) (P<0.01). Additionally, the TE3-MAL transfectant cells exhibited decreased cellular motility, a G1/S transition block and increased levels of apoptosis, concomitant with increased expression of Fas receptor in vitro. The apoptotic staining in MAL-expressing tumors was confirmed by TUNEL assay. Therefore, we conclude that expression of MAL was frequently decreased or diminished in gastrointestinal tract cancers, and that Mal expression confers reduced tumorigenicity in vivo to tumor TE3 cells through the induction of apoptosis via the Fas signaling pathway.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Abbott BD, Schmid JE, Brown JG, Wood CR, White RD, Buckalew AR and Held GA . (1999). Toxicol. Sci., 47, 76–85.

  • Alonso MA and Weissman SM . (1987). Proc. Natl. Acad. Sci. USA, 84, 1997–2001.

  • Cameron EE, Bachman KE, Myohanen S, Herman JG and Baylin SB . (1999). Nat. Genet., 21, 103–107.

  • Cheong KH, Zacchetti D, Schneeberger EE and Simons K . (1999). Proc. Natl. Acad. Sci. USA, 96, 6241–6248.

  • Dong JT . (2001). Cancer Metast. Rev., 20, 173–193.

  • Kim T, Fiedler K, Madison DL, Krueger WH and Pfeiffer SE . (1995). J. Neurosci. Res., 42, 413–422.

  • Konrad M, Saunier S, Heidet L, Silbermann F, Benessy F, Calado J, Le Paslier D, Broyer M, Gubler MC and Antignac C . (1996). Hum. Mol. Genet., 5, 367–371.

  • Martin-Belmonte F, Arvan P and Alonso MA . (2001). J. Biol. Chem., 276, 49337–49342.

  • Martin-Belmonte F, Kremer L, Albar JP, Marazuela M and Alonso MA . (1998). Endocrinology, 139, 2077–2084.

  • Martin-Belmonte F, Puertollano R, Millan J and Alonso MA . (2000). Mol. Biol. Cell, 11, 2033–2045.

  • Matsuyama A, Inoue H, Shibuta K, Tanaka Y, Barnard GF, Sugimachi K and Mori M . (2001). Cancer Res., 61, 5714–5717.

  • Millan J and Alonso MA . (1998). Eur. J. Immunol., 28, 3675–3684.

  • Millan J, Puertollano R, Fan L, Rancano C and Alonso MA . (1997). Biochem. J., 321, 247–252.

  • Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, Abe R, Ueo H and Akiyoshi T . (1997). Br. J. Cancer, 76, 531–536.

  • Mori M, Inoue H, Mimori K, Shibuta K, Nakashima H, Haraguchi M, Tsuji K, Ueo H, Barnard G and Akiyoshi T . (1996). Ann. Surg., 224, 183–188.

  • Mori M, Mimori K, Inoue H, Barnard GF, Tsuji K, Nanbara S, Ueo H and Akiyoshi, T . (1995). Cancer Res., 55, 3417–3420.

  • Nishihira T, Hashimoto Y, Katayama M, Mori S and Kuroki T . (1993). J. Cancer Res. Clin. Oncol., 119, 441–449.

  • Puertollano R and Alonso MA . (1999). Mol. Biol. Cell, 10, 3435–3447.

  • Puertollano R, Li S, Lisanti MP and Alonso MA . (1997). J. Biol. Chem., 272, 18311–18315.

  • Puertollano R, Martinez-Menarguez JA, Batista A, Ballesta J and Alonso MA . (2001). Mol. Biol. Cell, 12, 1869–1883.

  • Saunier S, Calado J, Benessy F, Silbermann F, Heilig R, Weissenbach J and Antignac C . (2000). Am. J. Hum. Genet., 66, 778–789.

  • Shibata K, Tanaka S, Shiraishi T, Kitano S and Mori M . (1999). Cancer Res., 59, 1096–1101.

  • Shimada Y, Imamura M, Wagata T, Yamaguchi N and Tobe T . (1992). Cancer, 69, 277–284.

  • Shiraishi T, Mori M, Tanaka S, Sugimachi K and Akiyoshi T . (1998). Int. J. Cancer, 79, 175–178.

  • Sugimachi K, Matsuoka H, Ohno S, Mori M and Kuwano H . (1988). Br. J. Surg., 75, 1115–1118.

  • Tugores A, Rubio T, Rancano C and Alonso MA . (1997). DNA Cell Biol., 16, 245–255.

  • Wadler S, Zhang H, Cammer M and Hu XP . (1999). Anal. Biochem., 267, 24–29.

Download references

Acknowledgements

We thank Dr T Shimo-oka for essential advice, Dr M Okamoto for his fruitful suggestions also and to J Miyake for excellent technical assistance.

Author information

Authors and Affiliations

  1. Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, 874-0838, Japan

    Koshi Mimori, Takeshi Shiraishi, Kohjiro Mashino, Hideto Sonoda, Keishi Yamashita, Keiji Yoshinaga, Takaaki Masuda, Tohru Utsunomiya, Hiroshi Inoue & Masaki Mori

  2. Centro de Biologia Molecular ‘Severo Ochoa’, Universidad Autónoma de Madrid and Consejo Superior de Investigaciones Científicas, Madrid, Spain

    Miguel A Alonso

Authors
  1. Koshi Mimori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takeshi Shiraishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kohjiro Mashino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hideto Sonoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keishi Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Keiji Yoshinaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Takaaki Masuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tohru Utsunomiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Miguel A Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Hiroshi Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Masaki Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masaki Mori.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mimori, K., Shiraishi, T., Mashino, K. et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 22, 3463–3471 (2003). https://doi.org/10.1038/sj.onc.1206378

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206378

Keywords

This article is cited by

Search

Advanced search

Quick links